Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride Injection for Prevention of Postoperative Nausea and Vomiting
CTR20230606Phase 3Completed
- Sponsor
- Nanjing Zhengke Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Amisulpride injection with Placebo (2 arms). Primary endpoint: Complete response (CR) rate for postoperative nausea and vomiting within 24 hours. Started Mar 2023; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on CTR20230606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230606.